Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?

Ass. Prof. Joleen Hubbard and Ass. Prof. Yu Sunakawa discuss the Clinical Question: Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?